Cogent Biosciences, Inc. COGT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $241.21M-22.7% | $312.01M+149% | $125.3M-1.8% | $127.6M+1.3% | $126M+28.4% | ||
| $625.17M+6.2% | $588.75M+122% | $265.59M+141% | $110.25M-7.9% | $119.66M-36.7% | ||
| $877.8M-3.6% | $910.36M+129% | $397.24M+62.1% | $245.01M-3.1% | $252.88M-14.7% | ||
| $5.3M-2.9% | $5.46M+3.5% | $5.27M-9.8% | $5.85M-9.3% | $6.45M-0.2% | ||
| $903.01M-3.7% | $937.61M+120% | $425.93M+55.0% | $274.82M-3.2% | $283.8M-13.4% | ||
| $13.74M+44.6% | $9.5M-40.7% | $16.03M-3.6% | $16.63M+17.5% | $14.15M+17.8% | ||
| $57.98M-9.3% | $63.95M+2.7% | $62.25M+6.5% | $58.42M+18.5% | $49.32M-11.5% | ||
| $295.31M-2.0% | $301.24M+144% | $123.47M+3.1% | $119.78M+84.8% | $64.8M-9.5% | ||
| $171K+6.2% | $161K+14.2% | $141K+23.7% | $114K0.0% | $114K+3.6% | ||
| -$1.29B-8.2% | -$1.19B-9.4% | -$1.09B-8.1% | -$1B-7.9% | -$931.47M-8.4% | ||
| $607.69M-4.5% | $636.37M+110% | $302.46M+95.1% | $155.04M-29.2% | $219M-14.6% | ||
| $903.01M-3.7% | $937.61M+120% | $425.93M+55.0% | $274.82M-3.2% | $283.8M-13.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cogent Biosciences, Inc.'s total assets?
- Cogent Biosciences, Inc. (COGT) holds $903.0M in total assets, up 218.2% year over year.
- How much debt does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. carries $15.5M in total debt against $607.7M of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. holds $241.2M in cash and equivalents.
- Can Cogent Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 15.14 — current assets exceed current liabilities.
- Where does Cogent Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
